GSK adds jobs, capabilities to Canadian plant; Abbott's patent victory over J&J to stand;

@FiercePharma: Laid-off Pfizer reps join OT lawsuit. News | Follow @FiercePharma

> GlaxoSmithKline is investing more than $30 million to add dermatology product manufacturing capabilities and create 70 jobs at a Canadian plant. Article

> Abbott Laboratories' victory in overturning a $1.67 billion patent-infringement verdict won by Johnson & Johnson will stand, a U.S. appeals court said yesterday. Report

> British Prime Minister David Cameron announced major revisions to his planned changes for the state-run health service after his original blueprint drew criticism from doctors and members of his own coalition government, who called it a partial privatization of the system. Item

> Swiss Stock Exchange officials are investigating an unusual jump in the shares in Swiss medical device maker Synthes before its takeover by Johnson & Johnson, the Wall Street Journal said. Item

> Watson Pharmaceuticals confirmed it is applying for approval to market a generic version of Novartis' Pataday eye drops after the brand's owners filed a lawsuit to prevent its commercialization. Report

> Injectables maker APP Pharmaceuticals has expanded its Grand Island, NY, manufacturing facility by 13,000 square feet with a $38 million investment. Story

> GlaxoSmithKline purchased for cancellation 1 million of its own shares, with the highest price paid at 1295 pence per share. News

> Shareholders of Detroit-based Caraco Pharmaceutical Laboratories, majority-owned by Sun Pharmaceuticals, voted to become a private company. Story

> ProStrakan has launched its cancer pain drug Abstral in Canada, where it will be sold by its Canadian partner Paladin Labs. Article

Biotech News

@FierceBiotech: Cancer immunotherapies in vogue as specialists seek a "cure." Story | Follow @FierceBiotech

@JohnCFierce: NIH is handing out $200M to five institutions for translational med work. Item | Follow @JohnCFierce

> NIH fast tracks $720M for new drug discovery center. Article

> Sanofi forges Boston R&D Hub in scramble to absorb Genzyme. News

> Lundbeck nails PhIII for drug to curb alcohol dependence. Story

Drug Delivery News

> Pfizer, pSivida deal is about big market in patient compliance. Piece

> New delivery system gives Parkinson's patients better quality of life. Article

> Mist inhaler to treat lung disease may not be safe. Report

> UK company looks to move from nutraceuticals to pharmaceuticals. Story

> Nanoparticle delivery into inner ear may help hearing loss. Article

> Singapore scientists design hydrogels that react to pH, temperature. Item

Medical Device News

> Covidien to shake up management structure. News

> Cordis to rein in stent development, cut jobs. Item

> QIAGEN looks to buy Ipsogen. Report

> CerebralRx's FitNes system launched in Europe. Article

> Secant to work with Solvant on biomedical implants. Story

> Spinal Modulation snags $30M in Series D. Report

And Finally... It's all about the dopamine, says Dr. Nora Volkow, neuroscientist in charge of the National Institute on Drug Abuse. Story

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.